Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RESGEX
- Sponsors Glycotope
- 28 Oct 2017 This study has been Discontinued in Spain
- 13 Oct 2017 Trail has been Discontinued in Poland.
- 13 Oct 2017 This study has been completed in Belgium as per European Clinical Trials Database.